US2011206794A1PendingUtilityA1

Fruit extracts

53
Assignee: PROVEXIS NATURAL PRODUCTS LTDPriority: Oct 31, 2008Filed: Nov 2, 2009Published: Aug 25, 2011
Est. expiryOct 31, 2028(~2.3 yrs left)· nominal 20-yr term from priority
Inventors:Niamh O'Kennedy
A61P 9/10A61P 9/00A61P 43/00A61P 7/02A61P 7/00A61K 31/7048A61K 36/81A61K 31/7064A01N 65/00A61K 36/00
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided are methods of making an extract of fruit of the Solanaceae family wherein fruit is processed to optimise the platelet aggregation inhibiting activity of the extract. The methods involve preparing a start mix of homogenised fruit; separating a water soluble fraction from fruit solids; filtration of the water soluble fraction; and concentration of active agents in the filtration permeate. The invention also provides fruit extracts manufactured by such methods, and also fruit extracts containing glycolsylated phenolic acid or a phenolic ester, or derivatives thereof; a glycosylated flavonoid; and a nucleoside. The extracts of the invention are useful as medicaments for the treatment or prevention of a medical condition characterised by inappropriate platelet aggregation. In particular, the medicaments may be of use in maintaining heart health by reducing platelet aggregation; benefiting the circulation; and/or normalizing or otherwise benefiting blood flow.

Claims

exact text as granted — not AI-modified
1 . A method of making an extract of fruit of the Solanaceae family wherein fruit is processed to optimise the platelet aggregation inhibiting activity of the extract comprising the steps of:
 (a) preparing a start mix of homogenised fruit;   (b) separating a water soluble-fraction from fruit solids;   (c) filtering the water soluble fraction; and   (d) concentrating active agents in the filtration permeate.   
     
     
         2 . The method according to  claim 1  wherein the holding temperature of the start mix does not exceed 35° C. 
     
     
         3 . The method according to  claim 1  wherein the pH of the start mix does not exceed 5.5 
     
     
         4 . The method according to  claim 1  wherein the browning index of the start mix, defined as the absorbance of the soluble portion at 420 nm, does not exceed 0.4 AU at 4% solids. 
     
     
         5 . The method according to  claim 1  wherein step (b) separates the fraction from insoluble solids with particle size >500μ. 
     
     
         6 . The method according to  claim 1  wherein step (b) does not involve a procedure that raises the temperature of the fraction above 60° C. 
     
     
         7 . The method according to  claim 1  wherein step (c) results in a solution that will pass through a 0.2μ filter without loss of solids. 
     
     
         8 . The method according to  claim 1  wherein step (d) does not involve a procedure that raises the temperature of the fraction above 60° C. 
     
     
         9 . The method according to  claim 1 , further comprising after step (c), the step of removing free, sugars from the water soluble extract. 
     
     
         10 . The method according to  claim 9  wherein the sugars are removed by resin-mediated separation of the extract components. 
     
     
         11 . A method of making an extract of fruit essentially as described in Examples 2 or 3. 
     
     
         12 . A. fruit extract prepared according to the method defined by  claim 1 . 
     
     
         13 . A fruit extract comprising:
 (a) glycosylated phenolic acid or a phenolic ester, or derivatives thereof;   (b) a glycosylated flaVonoid; and   (c) a nucleoside.   
     
     
         14 . The fruit extract according to  claim 13  wherein the glycosylated phenolic acid or a phenolic ester is a glycosylated cinnamic acid or derivative thereof. 
     
     
         15 . The fruit extract according to  claim 14  wherein the glycosylated cinnamic acid or derivative thereof is selected from the group consisting of Caffeoyl-4-O-quinic acid, Caffeoyl-4-O-glucoside, Coumaroyl-4-O-glycoside (glue/gal) and Coumaroyl-4-O-glycoside (disaccharide). 
     
     
         16 . The fruit extract according to  claim 13  wherein the glycosylated phenolic acid or a phenolic ester is selected from Caffeic acid glucoside, p-Coumaric acid hexose/dihydrokaempferol hexose, Ferulic acid glycoside, and a p-Coumaric acid derivative. 
     
     
         17 . The fruit extract according to  claim 13  wherein the glycosylated flavonoid is Quercetin-3-O-glucoside or. Rutin. 
     
     
         18 . The fruit extract according to  claim 13  wherein the nucleoside is selected from the group comprising AMP, Uridine, Adenosine, Guanosine or GMP. 
     
     
         19 . The fruit extract according to  claim 13  wherein the extract comprises each of the 16 compounds identified in table 1. 
     
     
         20 . The fruit extract according to  claim 13  wherein the extract comprises each of the 32 compounds identified in table 2. 
     
     
         21 . A fruit extract essentially as defined in Examples 2 or 3 
     
     
         22 . A method for the treatment or prevention of a medical condition in a subject characterised by inappropriate platelet aggregation, comprising:
 (a) providing a fruit extract according to  claim 12 ; and   (b) administering the fruit extract to the subiect to treat or prevent the medical condition.   
     
     
         23 . The method according to  claim 22 , wherein the treatment or prevention of the medical condition characterised by inappropriate platelet aggregation is for a purpose selected from the group consisting of: maintaining heart health by reduding platelet aggregation; benefiting the circulation; and normalizing or otherwise benefiting blood flow. 
     
     
         24 . A method for the treatment or prevention of a medical condition in a subject characterised by inappropriate platelet aggregation, comprising:
 (a) providing a fruit extract according to  claim 13 ; and   (b) administering the fruit extract to the subject to treat or prevent the medical condition.   
     
     
         25 . The method according to  claim 24 , wherein the treatment or prevention of the medical condition characterised by inappropriate platelet aggregation is for a purpose selected from the group consisting of maintaining heart health by reducing platelet aggregation; benefiting the circulation; and normalizing or otherwise benefiting blood flow. 
     
     
         26 . A method for the treatment or prevention of a medical condition in a subject characterised by inappropriate platelet aggregation, comprising:
 (a) providing a fruit extract according to  claim 21 ; and   (b) administering the fruit extract to the subject to treat or prevent the medical condition.   
     
     
         27 . The method according to  claim 26 , wherein the treatment or, prevention of the medical condition characterised by inappropriate platelet aggregation is for a purpose selected from the group consisting of: maintaining heart health by reducing platelet aggregation; benefiting the circulation; and normalizing or otherwise benefiting blood flow.

Join the waitlist — get patent alerts

Track US2011206794A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.